GlassScriptPhysician profile
Judith Cenci
NPI 1053308932
$11,389.81
in general payments reported to CMS, 2019-2025
39 companies · $1,323 in 2025
The $1,323 reported for 2025 was more than what 91% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,517 · 2020: $897 · 2021: $1,675 · 2022: $1,969 · 2023: $1,226 · 2024: $1,783 · 2025: $1,323.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,332.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,331.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,562.07 | 2019-2025 | Rinvoq, Skyrizi, Botox |
| Janssen Biotech, INC. | $1,261.52 | 2019-2025 | Tremfya |
| Galderma Laboratories, L.P. | $815.27 | 2019-2025 | Nemluvio, Aklief, Dysport |
| Sun Pharmaceutical Industries INC. | $645.94 | 2019-2025 | Ilumya |
| E.R. Squibb & Sons, L.L.C. | $560.74 | 2022-2025 | Sotyktu |
| Merz North America, INC. | $558.59 | 2019-2022 | |
| Lilly USA, LLC | $555.94 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Novartis Pharmaceuticals Corporation | $516.25 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $459.28 | 2019-2025 | Dupixent, Libtayo |
| Leo Pharma INC. | $418.57 | 2019-2025 | Adbry |
| Dermavant Sciences, INC. | $409.10 | 2022-2024 | Vtama |
| Genzyme Corporation | $380.06 | 2019-2025 | |
| Amgen INC. | $216.99 | 2020-2023 | Otezla |
| Ucb, INC. | $213.92 | 2019-2024 | Bimzelx, Cimzia |
| Celgene Corporation | $212.25 | 2019 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Judith Cenci listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.